CLOVIS ONCOLOGY, INC.
CHARTER OF THE SCIENTIFIC REVIEW COMMITTEE
OF THE BOARD OF DIRECTORS

The Charter of the Scientific Review Committee is established as follows.

PURPOSE

The purpose of the Scientific Review Committee (the "Committee") of the Board of Directors (the "Board") of Clovis Oncology, Inc. (the "Company"), is to advise the Board regarding the Company's research and development strategies and to perform such other functions as may be deemed necessary or convenient in carrying out the foregoing.

COMPOSITION

The Committee shall be appointed by the Board and may be removed, with or without cause, by the Board. The Committee shall consist of two (2) or more directors, as determined by the Board from time to time, who have relevant prior experience with discovery and pre-clinical research programs, clinical development and/or related regulatory matters with respect of pharmaceutical products. Each Committee member shall serve until a successor to such member is duly elected by the Board and qualified or until such member's resignation or removal from the Board or the Committee. The Chairman of the Committee shall be designated by the Board. The majority of the members of the Committee shall meet the applicable independence requirements of The Nasdaq Stock Market, Inc. ("NASDAQ") and any other applicable laws and regulations.

DUTIES AND RESPONSIBILITIES

In addition to any such other duties as the Board may from time to time assign, the Committee shall have the following responsibilities:

1. Provide strategic advice and make recommendations to the Board regarding the Company's pre-clinical and clinical product pipeline in view of the Company's overall strategy and vision.

2. Advise the Board regarding the scientific merit of technology or products involved in licensing and acquisition opportunities.

3. Keep the Board apprised regarding emerging science and technology issues and trends that may be relevant to the Company and its business.

4. Review scientific presentations containing initial disclosures of data from clinical trials that are anticipated to form the basis of safety and efficacy claims for new indications that are material to the Company.

5. Review plans for significant filings or submissions by the Company to the U.S. Food and Drug Administration (FDA), or similar non-U.S. agency, and reports from significant interactions with FDA (e.g., Type B or Type C meetings) or similar non-U.S. agency.

6. Receive reports on material deviations from any agreements, protocols or understandings with the FDA or similar non-U.S. agency governing the conduct of the Company's clinical trials, tests, or other studies or analyses, and evaluate the need for remedial action and/or disclosure.

7. Review plans for the design, conduct and public disclosure of results and data for all clinical trials intended to support marketing authorizations for new indications of the Company's product candidates.

MEETINGS

The Committee will hold at least four regular meetings per year and additional meetings as the Committee deems appropriate or as may be called by the Committee's Chairman or the Chairman of the Board. The presence in person or by telephone of a majority of the Committee's members shall constitute a quorum for any meeting of the Committee. Actions may be taken by the Committee upon the affirmative vote of a majority of its members present at a meeting of the Committee at which a quorum is present, unless a greater number is required by applicable law or the Company's certificate of incorporation or bylaws, or without a meeting if all of the members of the Committee indicate their approval in writing. The Chairman of the Board, the Chief Executive Officer, the Chief Medical Officer, the Chief Scientific Officer, the Chief Regulatory Officer and the General Counsel and any other officers or directors that are invited by the Committee, may attend any meeting of the Committee. Notwithstanding the foregoing, the Committee may exclude from its meetings any persons it deems appropriate. The Committee may form and delegate authority to subcommittees consisting of one or more members when appropriate; provided that the decisions of such subcommittee shall be presented to the full Committee at its next scheduled meeting.

The Committee is authorized, without further action by the Board, to engage such independent legal advisors, search firms and other advisors as it deems necessary or appropriate to carry out its responsibilities. The Committee is empowered, without further action by the Board, to cause the Company to pay the compensation of such advisors as established by the Committee. The Committee may also utilize the services of the Company's legal counsel or other advisors to the Company.

MINUTES AND REPORTS

The Chairman of the Committee shall consult with Company management and members of the Committee in the process of establishing agendas for Committee meetings. Minutes of each meeting of the Committee shall be prepared and distributed to each member of the Committee. The Committee shall report to the Board from time to time or whenever requested to do so by the Board. A copy of the minutes of each meeting and each written consent to action taken without a meeting shall be placed in the Company's minute book.

CHARTER AMENDMENT

By a majority vote, the Board may approve amendments to this Charter.